This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Stocks in play: Eupraxia Pharmaceuticals Inc.
Announced the first release of sub score data from the Eosinophilic Esophagitis Histologic Scoring System in its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis. These data were also presented this week at the Digestive Disease Week conference in Chicago. Eupraxia Pharmaceuticals Inc. shares T.EPRX are trading unchanged at $9.88.
